Jump to any asset
850 assets, updated daily
As of September 11, 2026, CRISPR Therapeutics AG (CRSP) trades at $52.16. CleaRank Financial AI rates it Hold with a fair value of $77.89, 49.3% above the current price. Wall Street's consensus target is $80.00 across 22 analysts. RSI at 26 is in oversold territory, and the price is below its 50-day average of $53.58.
CRISPR Therapeutics AG (CRSP)
CRISPR Therapeutics AG NASDAQ
$52.16
-0.1000 (-0.19%)
Latest Price
AI Analyst Consensus
59 / 100
CRISPR Therapeutics AG (CRSP) is currently trading at $52.16, below its 50-day and 200-day moving averages ($53.58 and $53.28), indicating a bearish technical trend. Despite this, the company exhibits strong insider selling, with insiders being net buyers to the tune of $52.7 million versus $19.5 million in sales, signaling confidence in the company's future prospects. Wall Street analysts maintain a 'Hold' consensus with a median price target of $80.00, suggesting a potential upside of 53.4% from current levels. The company is in the Biotechnology industry within the Healthcare sector, a field known for innovation and significant growth potential, but also inherent volatility and regulatory risks. The company's financial performance shows a substantial revenue growth of 1041.4% (from a very low base), with forward revenue estimates for the next year projecting a 283.00% increase, albeit with a capped average estimate suggesting potential outlier influence. The recent earnings report for July 2026 showed a slight beat on EPS, continuing a mixed but generally improving trend. However, the current oversold RSI of 26.28 suggests the stock may be due for a bounce, but the overall trend remains bearish until key resistance levels are reclaimed.
CRSP Price Analysis
Market Metrics
Open
$52.68
Day Range
$51.95 to $53.21
Prev Close
$52.26
Volume
15.6K
52-Week Range
$44.12 to $78.48
Market Cap
$5.05B
Peer Benchmarking
Valuation vs Sector (Healthcare)
Performance vs XLV
Sector Position Analysis
On price-to-sales, the yardstick used here in place of P/E, CRSP trades at 377.33x, far above the sector average of 4.20x.
CRSP Analysis
Company's Health
4/5
AI Technical Analysis
CRISPR Therapeutics AG (CRSP) is currently exhibiting bearish momentum, with its Relative Strength Index (RSI) at 26.28, indicating an oversold condition. The stock is trading below its 50-day and 200-day moving averages ($53.58 and $53.28), reinforcing the downward trend. The MACD is slightly negative at -0.007, further supporting the bearish sentiment. Key support levels are being tested, and the current price action suggests potential for a near-term bounce given the oversold RSI. However, until CRSP can reclaim its 50-day and 200-day moving averages, the overall technical picture remains weak. Volume has been significantly below average recently, suggesting a lack of conviction in the current price action.
ProTips
- Given the current oversold RSI and strong insider buying, consider monitoring CRSP for potential entry points as it consolidates or shows signs of a technical reversal.
- The significant revenue growth and future projections for CRISPR Therapeutics AG warrant close attention to clinical trial progress and regulatory milestones as key drivers of future performance.
- As a company in the highly innovative but volatile Biotechnology sector, maintain a diversified portfolio and consider position sizing carefully to manage the inherent risk associated with companies like CRSP.
Key Catalysts
Bullish
Insider Net Buying Activity
Insiders have demonstrated strong conviction by purchasing $52.7 million in stock versus $19.5 million in sales, signaling confidence in the company's future prospects.
Source: Insider Trading DataBullish
Strong Revenue Growth and Projections
CRISPR Therapeutics AG has reported exceptional revenue growth of 1041.4%, with next year's revenue projected to increase by 283.00%, indicating significant market traction and expansion potential.
Source: Wall Street Revenue EstimatesBullish
Median Analyst Price Target Upside
The median analyst price target of $80.00 suggests a potential upside of 53.4% from the current stock price of $52.16, indicating Wall Street's belief in future appreciation.
Source: Wall Street SummaryBearish
Bearish Technical Trend
CRSP is trading below its 50-day and 200-day moving averages ($53.58 and $53.28), with an oversold RSI of 26.28, indicating bearish momentum that could persist in the short term.
Source: Technical Analysis DataBearish
Lack of Profitability
The company currently has a negative EPS of -4.71, highlighting ongoing profitability challenges that could weigh on valuation and investor sentiment.
Source: Fundamental Analysis DataMarket Outlook
CRISPR Therapeutics AG (CRSP) is positioned for significant long-term growth, driven by its pioneering gene-editing technology and substantial revenue expansion. The base case scenario anticipates the stock to move towards its median analyst price target of $80.00 within the next 6-12 months, representing a potential upside of over 53%. This outlook is supported by strong insider conviction and promising forward revenue estimates. However, the trajectory could be altered by several factors. Upside catalysts include successful clinical trial results and regulatory approvals, which could significantly boost investor confidence and valuation. Conversely, downside risks include continued unprofitability, potential setbacks in clinical development, increased competition within the gene-editing space, and broader sector headwinds. The current oversold technical conditions may offer a near-term bounce, but sustained recovery will depend on fundamental improvements and overcoming existing bearish technicals.
Key Statistics
| Market Cap | 5.05B |
|---|---|
| P/E Ratio | N/A (Negative EPS) |
| EPS (TTM) | -4.71 |
| Dividend Yield | 0.00% |
| 52 Week High | 78.48 |
| 52 Week Low | 44.12 |
CRISPR Therapeutics AG (CRSP) presents a mixed fundamental picture, with a negative EPS of -4.71 rendering its P/E ratio mathematically negative, indicating it is not yet profitable on a per-share basis. Despite this, the company has demonstrated exceptional revenue growth of 1041.4% (from a very low base), and forward estimates project continued strong growth, with next year's revenue expected to increase by 283.00%. The current price of $52.16 is well below the median analyst price target of $80.00, suggesting potential undervaluation relative to future growth expectations. While the company's high revenue growth is a positive indicator, the lack of profitability and the significant upside potential implied by the analyst target price suggest that investors are pricing in substantial future success. The balance sheet strength and cash position would be critical to assess for long-term viability, especially given the current negative EPS. The company operates in the Biotechnology sector, which often requires significant R&D investment before achieving profitability.
Earnings & Growth Analysis
CRISPR Therapeutics AG (CRSP) most recently reported an EPS of $0.89 for July 2026, beating the estimate of $0.87 by 2.3%, and the stock saw a 0.19% price increase following the announcement. Prior to this, the company reported a loss of -$1.28 in May 2026, missing estimates by 4.07%. The earnings trend shows a pattern of mixed results, with some quarters showing beats and others misses, but the most recent quarter indicates a positive step towards profitability.
Key Risks
CRISPR Therapeutics AG (CRSP) faces significant risks, including its current lack of profitability, as indicated by its negative EPS. The stock is also trading below key moving averages, signaling bearish technical momentum that could persist. Also, the Biotechnology sector is inherently volatile and subject to regulatory hurdles and lengthy development cycles, which could impact future growth and profitability.
Technical Indicators
| RSI (14) | 26.28 |
|---|---|
| MACD | -0.01 |
| SMA 50 | 53.58 |
| SMA 200 | 53.28 |
RSI
Oversold
SMA Cross
Neutral
Price vs SMA
Bearish
MACD
Neutral
Price is trading below the 50-day SMA, RSI at 26.3 suggests oversold conditions; potential bounce setup.
Market Correlations
How this stock moves relative to other assets
Based on 1 year of daily price data. Correlations may vary over different time periods.
S&P 500 (SPY)
+0.41
Moderate correlation
Nasdaq 100 (QQQ)
+0.40
Weak correlation
Bitcoin (BTC)
+0.16
Weak correlation
Gold (XAU)
+0.16
Weak correlation
Check Custom Correlation
Calculating correlation...
CRSP Trade Plans
Specific entry, exit, and risk management levels
Select Your Trade Bias
Risk Tolerance
Conservative
2%
Aggressive
Portfolio Value
$
Position Size: Enter portfolio size →
Entry Strategies (click to switch)
CONSERVATIVE
$51.64
Slight discount to current
Wait for small dip
AGGRESSIVE
$52.16
At current price
Enter now if confident
Risk Management
STOP LOSS
$48.64
MAX LOSS
-5.8%
Volatility-Adjusted Stop Loss
Calculated based on RSI (26.3) and current market volatility
Profit Targets (Based on Conservative Entry)
TARGET 1
$53.19
+3% (Conservative)
+2.0% (Aggressive)
TARGET 2
$54.22
+5% (Conservative)
+4.0% (Aggressive)
TARGET 3
$55.77
+8% (Conservative)
+6.9% (Aggressive)
Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3
Calculate Your Trade
High-Volatility Risk Disclaimer
CRSP is classified as a high-volatility asset (Daily Vol: 3.52%). Aggressive price swings can lead to rapid capital loss. Liquidity risks may prevent exiting trades at desired prices. This AI-generated analysis is for educational purposes only and is not financial advice. Generated on September 11, 2026.Growth of $10,000
A $10,000 investment in CRSP in October 2016 would be worth about $37,090 today, compared with about $35,366 for the same investment in the S&P 500 benchmark.
Compare with Another Ticker
Monte Carlo Projection (10yr)
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in CRSP today could grow to about $27,251 by 2036 in the base case, with a bull case near $206,740 and a bear case around $3,592. Projections are statistical simulations, not guarantees.
CRSP Stock Price Prediction: 2030
CleaRank's simulation projects a price near $77.89 for CRSP by 2030 in the base case, from $52.16 today (1.5x over 4 years). The downside path ends near $21.62. These are outcomes of a Monte Carlo simulation run on CRSP's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | Downside (10th pct) | Base case | Upside (90th pct) |
|---|---|---|---|
| 2027 | $30.38 | $57.66 | $109 |
| 2028 | $25.75 | $63.74 | $158 |
| 2029 | $23.22 | $70.46 | $214 |
| 2030 | $21.62 | $77.89 | $281 |
| 2031 | $20.55 | $86.10 | $361 |
| 2032 | $19.81 | $95.18 | $457 |
| 2033 | $19.31 | $105 | $573 |
| 2034 | $18.99 | $116 | $712 |
| 2035 | $18.81 | $129 | $879 |
| 2036 | $18.74 | $142 | $1,078 |
Method: 10,000 simulated price paths using CRSP's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. CRSP is highly volatile, so its upside column reaches an extreme multiple; treat it as a statistical tail, not an expectation. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice.
People Also Watch
CRSP Insider Trading Analysis
Bought
$52.7M
3 Transactions
Sold
$19.5M
29 Transactions
Insiders
8
Active Traders
Avg Transaction
$2.3M
Large trades
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| May 14, 2018 | EMSTER KURT VON
Director
|
Sell | 650.0K | $35.4M |
| Dec 7, 2020 | BOLZON BRADLEY J
Director
|
Sell | 171.0K | $26.4M |
| Feb 19, 2021 | BOLZON BRADLEY J
Director
|
Sell | 171.0K | $25.5M |
| Dec 4, 2017 | CELGENE CORP
Beneficial Owner of more than 10% of a Class of Security
|
Sell | 1.1M | $21.1M |
| Mar 23, 2021 | KLEIN LAWRENCE OTTO
Chairman of the Board
|
Sell | 100.0K | $12.8M |
| Nov 30, 2020 | NOVAK RODGER
President
|
Sell | 100.0K | $12.5M |
| Apr 27, 2018 | BOLZON BRADLEY J
Director
|
Sell | 222.3K | $11.1M |
| Apr 27, 2018 | WOIWODE THOMAS
Director
|
Sell | 222.3K | $11.1M |
| Jun 29, 2021 | BOLZON BRADLEY J
Director
|
Sell | 47.5K | $7.1M |
| May 8, 2018 | BOLZON BRADLEY J
Director
|
Sell | 129.0K | $6.5M |
Page 1 of 1
Frequently Asked Questions
What is CRISPR Therapeutics AG's stock price prediction for 2030?
CRISPR Therapeutics AG's stock price is projected to be $77.89 by 2030 based on a Monte Carlo simulation's base case. The downside projection is $21.62, while the upside projection reaches $280.59. These figures represent statistical simulation outcomes, not guaranteed price targets.
Is CRISPR Therapeutics AG stock a buy right now?
CRISPR Therapeutics AG (CRSP) is currently rated a 'Hold' by Wall Street analysts, with a median price target of $80.00, suggesting a potential 53.4% upside from its current price of $52.16. While insider sentiment is positive and revenue growth is strong, the stock is trading below its key moving averages, indicating bearish technical momentum.
What are the biggest risks facing CRISPR Therapeutics AG?
The primary risks for CRISPR Therapeutics AG include its current unprofitability, evidenced by a negative EPS, and its bearish technical trend, trading below key moving averages. The volatile nature of the Biotechnology sector, with its regulatory challenges and long development timelines, also poses a significant risk.
How is CRISPR Therapeutics AG performing financially?
CRISPR Therapeutics AG has demonstrated exceptional revenue growth of 1041.4% (from a very low base) and projects further strong growth for next year. However, the company currently has a negative EPS of -4.71, indicating it is not yet profitable.
What is the Wall Street consensus for CRISPR Therapeutics AG?
The Wall Street consensus for CRISPR Therapeutics AG (CRSP) is 'Hold', with a score of 70 out of 100. This is based on 22 analysts, with 5 rating it 'Strong Buy', 8 'Buy', and 9 'Hold'.
What is CRISPR Therapeutics AG's current technical standing?
CRISPR Therapeutics AG (CRSP) is currently in an oversold technical position with an RSI at 26.3. The stock is trading below its 50-day and 200-day moving averages ($53.58 and $53.28), indicating bearish momentum, though the oversold condition may suggest a potential for a bounce.
Are insiders buying or selling CRISPR Therapeutics AG stock?
Insiders at CRISPR Therapeutics AG are net buyers, having purchased $52.7 million worth of stock compared to $19.5 million in sales. This 'Moderate Buy Signal' suggests a positive sentiment from management regarding the company's future.